| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 DJ Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, ... New England journal of medicine 344 (11), 783-792, 2001 | 14533 | 2001 |
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, ... New England Journal of Medicine 351 (27), 2817-2826, 2004 | 7402 | 2004 |
| Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer CL Vogel, MA Cobleigh, D Tripathy, JC Gutheil, LN Harris, ... Journal of clinical oncology 20 (3), 719-726, 2002 | 4259 | 2002 |
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed … MA Cobleigh, CL Vogel, D Tripathy, NJ Robert, S Scholl, L Fehrenbacher, ... Journal of clinical Oncology 17 (9), 2639-2639, 1999 | 3710 | 1999 |
| Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer S Paik, G Tang, S Shak, C Kim, J Baker, W Kim, M Cronin, FL Baehner, ... Journal of clinical oncology 24 (23), 3726-3734, 2006 | 3207 | 2006 |
| Cardiac dysfunction in the trastuzumab clinical trials experience A Seidman, C Hudis, MK Pierri, S Shak, V Paton, M Ashby, M Murphy, ... Journal of clinical oncology 20 (5), 1215-1221, 2002 | 1986 | 2002 |
| Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a … KS Albain, WE Barlow, S Shak, GN Hortobagyi, RB Livingston, IT Yeh, ... The lancet oncology 11 (1), 55-65, 2010 | 1671 | 2010 |
| Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer MS Gordon, K Margolin, M Talpaz, GW Sledge Jr, E Holmgren, ... Journal of Clinical Oncology 19 (3), 843-850, 2001 | 1230 | 2001 |
| Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. S Shak, DJ Capon, R Hellmiss, SA Marsters, CL Baker Proceedings of the National Academy of Sciences 87 (23), 9188-9192, 1990 | 906 | 1990 |
| Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with … M Dowsett, J Cuzick, C Wale, J Forbes, EA Mallon, J Salter, E Quinn, ... Journal of Clinical Oncology 28 (11), 1829-1834, 2010 | 873 | 2010 |
| A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling EA Klein, MR Cooperberg, C Magi-Galluzzi, JP Simko, SM Falzarano, ... European urology 66 (3), 550-560, 2014 | 766 | 2014 |
| Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor–positive breast cancer: results from NSABP B-14 … EP Mamounas, G Tang, B Fisher, S Paik, S Shak, JP Costantino, ... Journal of Clinical Oncology 28 (10), 1677-1683, 2010 | 673 | 2010 |
| Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer L Gianni, M Zambetti, K Clark, J Baker, M Cronin, J Wu, G Mariani, ... Journal of clinical oncology 23 (29), 7265-7277, 2005 | 665 | 2005 |
| 21-gene assay to inform chemotherapy benefit in node-positive breast cancer K Kalinsky, WE Barlow, JR Gralow, F Meric-Bernstam, KS Albain, ... New England Journal of Medicine 385 (25), 2336-2347, 2021 | 657 | 2021 |
| Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay M Cronin, M Pho, D Dutta, JC Stephans, S Shak, MC Kiefer, JM Esteban, ... The American journal of pathology 164 (1), 35-42, 2004 | 655 | 2004 |
| A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients LA Habel, S Shak, MK Jacobs, A Capra, C Alexander, M Pho, J Baker, ... Breast Cancer Research 8, 1-15, 2006 | 603 | 2006 |
| A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast LJ Solin, R Gray, FL Baehner, SM Butler, LL Hughes, C Yoshizawa, ... Journal of the National Cancer Institute 105 (10), 701-710, 2013 | 599 | 2013 |
| Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer … D Slamon Proc Am Soc Clin Oncol 17, 98a, 1998 | 500 | 1998 |
| Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator … S Shak Seminars in oncology 26 (4 Suppl 12), 71-77, 1999 | 485 | 1999 |
| Validation study of a quantitative multigene reverse transcriptase–polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer RG Gray, P Quirke, K Handley, M Lopatin, L Magill, FL Baehner, ... Journal of clinical oncology 29 (35), 4611-4619, 2011 | 453 | 2011 |
